Literature DB >> 23974892

Biological Stability of Plasma Rich in Growth Factors Eye Drops After Storage of 3 Months.

Eduardo Anitua1, Francisco Muruzabal, Ander Pino, Jesús Merayo-Lloves, Gorka Orive.   

Abstract

PURPOSE: We evaluated whether plasma rich in growth factors eye drops maintain their composition and biological activity after storage for 3 months at -20°C and after storage at 4°C or room temperature (RT) for 24 hours, compared with samples obtained at time 0 (fresh samples).
METHODS: Blood from 10 healthy donors was collected, centrifuged, and plasma rich in growth factors was prepared by avoiding the collection of the buffy coat. Eye drops were kept fresh or were stored at -20°C for 15, 30, and 90 days. For each time, 2 aliquots were kept at RT or at 4°C for 24 hours. Osmolarity, vitamin A, fibronectin, platelet-derived growth factor-AB, vascular endothelial growth factor, epithelial growth factor, and transforming growth factor-β1 were quantified. The proliferative and migratory potential of the eye drops was assayed on primary human keratocytes.
RESULTS: Platelet-derived growth factor-AB, vascular endothelial growth factor, epithelial growth factor, and vitamin A levels remained constant for each time and for each storage condition, whereas fibronectin, transforming growth factor-β1, and osmolarity values were slightly modified after freezing. Cell proliferation and migration were significantly enhanced with the biological eye drops independently of the time and the storage condition. No microbial contamination was observed in any plasma rich in growth factors eye drops.
CONCLUSIONS: Plasma rich in growth factors eye drops can be stored for up to 3 months without any reduction of the main proteins involved in ocular surface healing. Their use during 24 hours either at 4°C or at RT did not alter the composition and the in vitro biological activity of the eye drops.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23974892     DOI: 10.1097/ICO.0b013e31829f7088

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  16 in total

1.  Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops.

Authors:  Ronald Mauricio Sanchez-Avila; Jesus Merayo-Lloves; Ana Cristina Riestra; Luis Fernandez-Vega Cueto; Eduardo Anitua; Leire Begoña; Francisco Muruzabal; Gorka Orive
Journal:  Int Ophthalmol       Date:  2017-06-15       Impact factor: 2.031

2.  A novel personalized 3D injectable protein scaffold for regenerative medicine.

Authors:  Eduardo Anitua; Ander Pino; María Troya; Pedro Jaén; Gorka Orive
Journal:  J Mater Sci Mater Med       Date:  2017-12-14       Impact factor: 3.896

3.  Stability of epidermal growth factor, fibronectin, and alpha-2-macroglobulin in canine serum under different storage conditions.

Authors:  Cecile Briffod; Christian Bédard; Maria Vanore
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

4.  Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases.

Authors:  Ronald M Sánchez-Ávila; Edmar Uribe-Badillo; Carlos Fernández-Vega González; Francisco Muruzabal; Borja de la Sen-Corcuera; Begoña Baamonde; Luis M Quirós; Eduardo Anitua; Jesús Merayo-Lloves
Journal:  Vision (Basel)       Date:  2021-07-02

5.  Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study.

Authors:  Jorge L Alio; Alejandra E Rodriguez; Renan Ferreira-Oliveira; Dominika Wróbel-Dudzińska; Ahmed A Abdelghany
Journal:  Ophthalmol Ther       Date:  2017-08-08

6.  Quantification of Growth Factors and Fibronectin in Diverse Preparations of Platelet-Rich Plasma for the Treatment of Ocular Surface Disorders (E-PRP).

Authors:  Alejandra E Rodriguez; Sandra Gisbert; Antonio Palazón; Jorge L Alio
Journal:  Transl Vis Sci Technol       Date:  2020-05-21       Impact factor: 3.283

7.  Plasma rich in growth factors versus Mitomycin C in photorefractive keratectomy.

Authors:  Ronald M Sanchez-Avila; Edmar E Uribe-Badillo; Javier Fernández-Vega Sanz; Francisco Muruzabal; Nancy Jurado; Belén Alfonso-Bartolozzi; Jose F Alfonso; Begoña Baamonde; Eduardo Anitua; Jesus Merayo-Lloves
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

8.  Leukocyte presence does not increase microbicidal activity of Platelet-rich Plasma in vitro.

Authors:  Erminia Mariani; Valentina Canella; Andrea Berlingeri; Alessandra Bielli; Luca Cattini; Maria Paola Landini; Elizaveta Kon; Maurilio Marcacci; Berardo Di Matteo; Giuseppe Filardo
Journal:  BMC Microbiol       Date:  2015-07-30       Impact factor: 3.605

9.  Development and Optimization of Freeze-Dried Eye Drops Derived From Plasma Rich in Growth Factors Technology.

Authors:  Eduardo Anitua; María de la Fuente; Ignacio Alcalde; Cristina Sanchez; Jesús Merayo-Lloves; Francisco Muruzabal
Journal:  Transl Vis Sci Technol       Date:  2020-06-25       Impact factor: 3.283

10.  Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors.

Authors:  Ronald M Sánchez-Ávila; Álvaro Fernández-Vega González; Álvaro Fernández-Vega Sanz; Jesús Merayo-Lloves
Journal:  Int Med Case Rep J       Date:  2019-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.